Dr. Mitchell

Edith P. Mitchell, MD, FACP

Contact Dr. Mitchell

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874
(215) 503-9506 fax

Most Recent Peer-reviewed Publications

  1. MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-Bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer
  2. Loss of nuclear localized parathyroid hormone-related protein in primary breast cancer predicts poor clinical outcome and correlates with suppressed STAT5 signaling
  3. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials
  4. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
  5. American Society of Clinical Oncology strategic plan for increasing racial and ethnic diversity in the oncology workforce
  6. Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer
  7. A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
  8. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: A phase II Eastern cooperative oncology group-American college of radiology imaging network cancer research group trial (E3205)
  9. Making the Case for Improving Oncology Workforce Diversity
  10. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials
  11. Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms
  12. African American Patients’ Psychosocial Support Needs and Barriers to Treatment: Patient Needs Assessment
  13. Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
  14. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy
  15. Moonshot Toward a Cure for Cancer
  16. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism
  17. Positive association of fibroadenomatoid change with HER2-negative invasive breast cancer: A co-occurrence study
  18. 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: A randomized Phase IIb study
  19. Efficacy endpoints of radiation therapy group protocol 0247: A randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer
  20. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer